| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 160.496 | 142.635 | - | 155.825 | 169.347 | 178.381 | 209.728 | 186.558 | 224.485 | 242.277 |
| Total Income - EUR | 166.371 | 148.509 | - | 157.385 | 170.411 | 179.098 | 209.741 | 186.840 | 224.496 | 242.290 |
| Total Expenses - EUR | 140.088 | 125.612 | - | 145.852 | 147.181 | 150.071 | 151.311 | 152.979 | 189.249 | 200.659 |
| Gross Profit/Loss - EUR | 26.283 | 22.897 | - | 11.533 | 23.230 | 29.027 | 58.431 | 33.861 | 35.247 | 41.631 |
| Net Profit/Loss - EUR | 22.092 | 17.661 | - | 9.959 | 21.524 | 27.375 | 56.333 | 31.991 | 33.001 | 35.169 |
| Employees | 4 | 7 | - | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
Check the financial reports for the company - Tanofarm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 31.305 | 37.225 | - | 52.047 | 49.727 | 46.877 | 64.419 | 57.594 | 51.607 | 45.819 |
| Current Assets | 85.157 | 76.569 | - | 36.661 | 25.961 | 33.763 | 50.572 | 38.643 | 40.221 | 46.147 |
| Inventories | 7.873 | 11.951 | - | 15.051 | 15.167 | 14.307 | 17.987 | 21.981 | 24.943 | 26.791 |
| Receivables | 67.081 | 45.931 | - | 4.728 | -609 | 1.200 | 2.175 | 320 | 334 | 3.747 |
| Cash | 10.203 | 18.686 | - | 16.883 | 11.403 | 18.256 | 30.410 | 16.343 | 14.943 | 15.609 |
| Shareholders Funds | 113.050 | 107.691 | - | 71.672 | 57.836 | 62.999 | 94.710 | 70.484 | 71.378 | 73.331 |
| Social Capital | 45 | 45 | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 4.452 | 6.102 | - | 17.036 | 17.853 | 17.641 | 20.282 | 25.753 | 20.450 | 18.634 |
| Income in Advance | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Tanofarm S.r.l.